AMGN
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FAMGN.O%2Fkey-developments%2Farticle%2F2774180&ei=n4aaUvD9OdO60AGuJw&usg=AFQjCNHcBGf2FqrjAtNanjC5xGyqP88XaA
Amgen Inc And Cytokinetics Announces Expansion Of License For Omecamtiv Mecarbil
Wednesday, 12 Jun 2013 07:30am EDT
Amgen Inc and Cytokinetics Incorporated announced an expansion of their strategic collaboration to include Japan. In 2006, Cytokinetics and Amgen entered into a collaboration to discover, develop and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for potential applications in the treatment of heart failure. Under the amendment to the collaboration announced , the companies have agreed on terms expanding Amgen's license for omecamtiv mecarbil and related compounds to include Japan. In consideration of the expanded license, Cytokinetics will receive $25 million from Amgen comprised of a non-refundable license fee of $15 million and $10 million for Amgen's purchase of Cytokinetics' common stock.Â 
